Global Processing

Teva’s MS Drug Misses Study Goal

August 1, 2011

Teva Pharmaceutical Industries Ltd. said its experimental drug laquinimod, an oral treatment for multiple sclerosis, did not reduce patients'' annual relapse rate in a late-stage clinical trial, Forbes reported. Shares of Teva, which also makes the injectable MS drug Copaxone, lost $2.69, or 5.8 percent, to $43.95 in afternoon trading. The results showed that laquinimod was not more effective than a placebo. The study involved 1,331 patients.